



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Felvizumab

Cat. No.:	HY-P99615
CAS No.:	167747-20-8
Target:	RSV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Felvizumab (SB 209763) is a humanized IgG1k monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV <sup>[1][2]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	EC <sub>50</sub> : 0.49 µg/mL (RSV Type A in microneutralization assay), 0.95 µg/mL (RSV Type A in fusion inhibition assay) <sup>[2]</sup> <b>Caution: Product has not been fully validated for medical applications. For research use only.</b>								
<b>In Vitro</b>	<p>Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com        Address: 1 Deer Park Dr, Suite O, Monmouth Junction, NJ 08852, USA</p> <p>Felvizumab (RSHZ19) (2 h or 4 h) inhibits RSV Type A with an EC<sub>50</sub> of 0.49 ± 0.37 µg/mL in microneutralization assay and with an EC<sub>50</sub> of 0.95 ± 0.13 µg/mL in fusion inhibition assay<sup>[2]</sup>.        MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
<b>In Vivo</b>	<p>Felvizumab (RSHZ19) (0.625-5.0 mg/kg; intramuscular injection; once) is effective against A and B subtypes of RSV in the cotton rat model of RSV infection<sup>[2]</sup>.        MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cotton rats, RSV infection model<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.625, 1.25, 2.5, and 5.0 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intramuscular injection, 1 day before infection</td> </tr> <tr> <td>Result:</td> <td>Significantly reduced lung RSV titer.</td> </tr> </table>	Animal Model:	Cotton rats, RSV infection model <sup>[2]</sup>	Dosage:	0.625, 1.25, 2.5, and 5.0 mg/kg	Administration:	Intramuscular injection, 1 day before infection	Result:	Significantly reduced lung RSV titer.
Animal Model:	Cotton rats, RSV infection model <sup>[2]</sup>								
Dosage:	0.625, 1.25, 2.5, and 5.0 mg/kg								
Administration:	Intramuscular injection, 1 day before infection								
Result:	Significantly reduced lung RSV titer.								

### REFERENCES

- [1]. Fenton C, et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs. 2004;6(3):177-97.
- [2]. Johnson S, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J Infect Dis. 1999 Jul;180(1):35-40.